These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 4567423)

  • 1. Antilipaemic drugs and nephrotic hyperlipidaemia.
    Edwards KD
    Prog Biochem Pharmacol; 1972; 7():370-426. PubMed ID: 4567423
    [No Abstract]   [Full Text] [Related]  

  • 2. Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia.
    Schapel GJ; Edwards KD; Neale FC
    Prog Biochem Pharmacol; 1974; 9():82-98. PubMed ID: 4438384
    [No Abstract]   [Full Text] [Related]  

  • 3. [Nephrotic hyperlipidemia and its clinical significance].
    Neverov NI; Srinivas KV
    Ter Arkh; 1990; 62(6):150-3. PubMed ID: 2218917
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
    Wheeler DC
    J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipolytic activity of kidney tissue in experimental nephrotic syndrome].
    Leĭtes SM; Nikiforova NV
    Vopr Med Khim; 1967; 13(4):404-8. PubMed ID: 5598540
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of hyperlipidemia].
    Müller G
    Dtsch Gesundheitsw; 1971 Oct; 26(43):2020-4. PubMed ID: 4947270
    [No Abstract]   [Full Text] [Related]  

  • 7. Clofibrate and androsterone effect on serum lipids.
    Orgain ES; Bogdonoff MD; Cain C
    Arch Intern Med; 1967 Jan; 119(1):80-5. PubMed ID: 6015838
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hyperlipemia in nephrotic syndrome].
    Walasek L
    Pol Tyg Lek; 1972 Jan; 27(5):189-91. PubMed ID: 4551652
    [No Abstract]   [Full Text] [Related]  

  • 9. [The treatment of essential hyperlipidemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
    Sterner W; Chibanguza G; Metz G
    Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyslipidemia in the nephrotic syndrome. Physiopathological aspects and therapeutic prospects].
    Campanacci L
    Minerva Nefrol; 1975; 22(6):243-51. PubMed ID: 1223701
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hyperlipoproteinemia in the nephrotic syndrome].
    Yasugi T; Shimizu T; Iijima M; Tomita M; Harada M
    Saishin Igaku; 1972 Mar; 27(3):504-9. PubMed ID: 5021394
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypolipidaemic action of gemfibrozil in adult nephrotics.
    Eisalo A; Manninen V; Mälkönen M; Kuhlbäck B
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):47-8. PubMed ID: 798197
    [No Abstract]   [Full Text] [Related]  

  • 14. The influence of drugs affecting lipids on atherosclerosis.
    Ditschuneit H
    Horm Metab Res; 1974; Suppl 4():191-4. PubMed ID: 4421312
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis of lipid abnormalities in patients with nephrotic syndrome/proteinuria: clinical implications.
    Warwick GL; Packard CJ
    Miner Electrolyte Metab; 1993; 19(3):115-26. PubMed ID: 8232098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipids and progressive kidney disease.
    Moorhead JF
    Kidney Int Suppl; 1991 Apr; 31():S35-40. PubMed ID: 2046269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid abnormalities in progressive renal insufficiency.
    Attman PO; Samuelsson O; Alaupovic P
    Contrib Nephrol; 1997; 120():1-10. PubMed ID: 9257042
    [No Abstract]   [Full Text] [Related]  

  • 18. [Recent trends in the therapy of hyperlipidemia in nephrotic syndrome].
    Campanacci L; Guarnieri GF; Faccini L; Bellini G; Gambari PF
    G Clin Med; 1973 Oct; 54(10):714-33. PubMed ID: 4789301
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid and lipoprotein abnormalities in renal disease.
    Segura R; Gotto AM
    Perspect Nephrol Hypertens; 1976; 3():159-200. PubMed ID: 814531
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antilipidemic agents].
    Irsigler K; Flegel U
    Int Z Klin Pharmakol Ther Toxikol; 1971 Dec; 5(3):334-40. PubMed ID: 5148890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.